Drug intelligence / Profile preview

iruplinalkib

Development stage: Phase 3
Lead developer: Qilu Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Iruplinalkib is an orally available, small molecule inhibitor of the anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases. It is developed by Qilu Pharmaceuticals for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with ALK-positive NSCLC. Iruplinalkib has shown efficacy against both wild-type ALK and ALK resistance mutations, such as L1196M and G1202R. It was approved in China for the treatment of ALK-positive, crizotinib-resistant or crizotinib-intolerable NSCLC.

Brand names: Qixinke
Other names: Z5F65W1YAZZ-5F65W1YAZZ 5F65W1YAZ

Targets

ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)EGFR (Epidermal growth factor receptor)SLC47A1 (Multidrug and toxin extrusion transporter 1)MATE2-K (Multidrug and toxin extrusion protein 2)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)

Beyond the preview

Go deeper on iruplinalkib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iruplinalkib.